Claudia S Crowell1, Paige L Williams2, Cenk Yildirim2, Russell B Van Dyke3, Renee Smith4, Ellen G Chadwick5, George R Seage2, Alexandria Diperna6, Rohan Hazra7. 1. Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington. 2. Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Tulane University School of Medicine, New Orleans, Louisiana. 4. University of Illinois at Chicago. 5. Northwestern University Feinberg School of Medicine, Chicago, Chicago, Illinois. 6. Frontier Science and Technology Research Foundation, Amherst, New York. 7. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Abstract
OBJECTIVE: To evaluate whether there is an increased risk of neurologic diagnoses in children who are HIV-exposed but uninfected (CHEU) exposed in utero to specific antiretroviral medications. DESIGN: Prospective cohort study of CHEU enrolled from 2007 to 2017. METHODS: We evaluated children for neurologic case status, including microcephaly, febrile seizures, seizure disorders, ophthalmologic disorders, and other neurologic disorders. Adjusted relative risks (aRRs) were estimated for the association between in-utero antiretroviral exposure and neurologic case using log-binomial regression, accounting for potential confounders. Sensitivity analyses were conducted to evaluate robustness of findings. RESULTS: Among 3747 eligible CHEU, 231 (6.2%) met neurologic case criteria (95% CI 5.4--7%). Most eligible children (86%) were exposed in utero to combination antiretroviral regimens. In adjusted models, children exposed to efavirenz at any time during pregnancy had higher risk of neurologic case status (aRR = 1.53, 95% CI 0.94--2.51). This association was stronger when comparing efavirenz exposure at conception to no exposure during pregnancy (aRR = 1.92, 95% CI 1.09--3.36) and considering follow-up and case diagnosis only through age 2 (aRR = 2.14, 95% CI 1.11--4.12). Children exposed to didanosine at conception and during the first trimester had increased risk of neurologic case status (aRR = 2.28, 95% CI 1.07--4.87 and aRR = 2.02, 95% CI 1.01--4.04, respectively), compared with didanosine-unexposed children. Children with dolutegravir exposure had some suggestion of increased risk of neurologic case (aRR = 2.43, 95% CI 0.75--7.84), which was observed consistently across several sensitivity analyses. CONCLUSION: Efavirenz and didanosine exposure during pregnancy were associated with higher risk of neurologic abnormalities in CHEU, and dolutegravir exposure showed some suggestive associations, which warrant further monitoring.
OBJECTIVE: To evaluate whether there is an increased risk of neurologic diagnoses in children who are HIV-exposed but uninfected (CHEU) exposed in utero to specific antiretroviral medications. DESIGN: Prospective cohort study of CHEU enrolled from 2007 to 2017. METHODS: We evaluated children for neurologic case status, including microcephaly, febrile seizures, seizure disorders, ophthalmologic disorders, and other neurologic disorders. Adjusted relative risks (aRRs) were estimated for the association between in-utero antiretroviral exposure and neurologic case using log-binomial regression, accounting for potential confounders. Sensitivity analyses were conducted to evaluate robustness of findings. RESULTS: Among 3747 eligible CHEU, 231 (6.2%) met neurologic case criteria (95% CI 5.4--7%). Most eligible children (86%) were exposed in utero to combination antiretroviral regimens. In adjusted models, children exposed to efavirenz at any time during pregnancy had higher risk of neurologic case status (aRR = 1.53, 95% CI 0.94--2.51). This association was stronger when comparing efavirenz exposure at conception to no exposure during pregnancy (aRR = 1.92, 95% CI 1.09--3.36) and considering follow-up and case diagnosis only through age 2 (aRR = 2.14, 95% CI 1.11--4.12). Children exposed to didanosine at conception and during the first trimester had increased risk of neurologic case status (aRR = 2.28, 95% CI 1.07--4.87 and aRR = 2.02, 95% CI 1.01--4.04, respectively), compared with didanosine-unexposed children. Children with dolutegravir exposure had some suggestion of increased risk of neurologic case (aRR = 2.43, 95% CI 0.75--7.84), which was observed consistently across several sensitivity analyses. CONCLUSION:Efavirenz and didanosine exposure during pregnancy were associated with higher risk of neurologic abnormalities in CHEU, and dolutegravir exposure showed some suggestive associations, which warrant further monitoring.
Authors: S Blanche; M Tardieu; P Rustin; A Slama; B Barret; G Firtion; N Ciraru-Vigneron; C Lacroix; C Rouzioux; L Mandelbrot; I Desguerre; A Rötig; M J Mayaux; J F Delfraissy Journal: Lancet Date: 1999-09-25 Impact factor: 79.321
Authors: Mmakgomo M Raesima; Chibuike M Ogbuabo; Vasavi Thomas; Sara E Forhan; Gadzikanani Gokatweng; Eldah Dintwa; Chipo Petlo; Catherine Motswere-Chirwa; Elizabeth M Rabold; Sarah C Tinker; Shifawu Odunsi; Sifelani Malima; Omphemetse Mmunyane; Thusoetsile Modise; Kelame Kefitlhile; Kunle Dare; Mpho Letebele; Michelle E Roland; Cynthia A Moore; Surbhi Modi; Dhelia M Williamson Journal: N Engl J Med Date: 2019-07-22 Impact factor: 91.245
Authors: Rebecca Zash; Lewis Holmes; Modiegi Diseko; Denise L Jacobson; Sean Brummel; Gloria Mayondi; Arielle Isaacson; Sonya Davey; Judith Mabuta; Mompati Mmalane; Tendani Gaolathe; M Essex; Shahin Lockman; Joseph Makhema; Roger L Shapiro Journal: N Engl J Med Date: 2019-07-22 Impact factor: 91.245
Authors: Lisa van de Wijer; Lidiane P Garcia; Sabrina I Hanswijk; Juliette Rando; Anthonieke Middelman; Rob Ter Heine; Quirijn de Mast; Gerard J M Martens; André J A M van der Ven; Sharon M Kolk; Arnt F A Schellekens; Judith R Homberg Journal: Transl Psychiatry Date: 2019-02-11 Impact factor: 6.222
Authors: Marie A Brault; Sten H Vermund; Muktar H Aliyu; Saad B Omer; Dave Clark; Donna Spiegelman Journal: Int J Environ Res Public Health Date: 2021-10-13 Impact factor: 3.390
Authors: Catherine J Wedderburn; Nynke A Groenewold; Annerine Roos; Shunmay Yeung; Jean-Paul Fouche; Andrea M Rehman; Diana M Gibb; Katherine L Narr; Heather J Zar; Dan J Stein; Kirsten A Donald Journal: J Int AIDS Soc Date: 2022-01 Impact factor: 6.707